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Objective: Decreased insulin-like growth factor-I (IGF-I) levels in adults have been associated with an
increased risk of ischemic heart disease and heart failure. It is currently unknown whether patients with low
circulating IGF-I levels due to a homozygous acid-labile subunit (IGFALS) gene mutation also have increased
risk of cardiovascular disease. Therefore, we evaluated atherosclerotic burden in a 27 year old male patient
who was diagnosed with a homozygous IGFALS mutation and consequently had extremely low circulating
IGF-I levels.
Methods: Ten year's cardiovascular risk was calculated using the Framingham risk score. Presence of
(subclinical) atherosclerosis was assessed using a 64-slice CT scan of the coronary arteries. Cardiac
performance was measured by conventional echocardiographic measurements, three dimensional (3D)-
echocardiography, and tissue deformation imaging.
Results: Despite his extremely low circulating IGF-I levels due to Acid-Labile Subunit (ALS) deﬁciency, our
patient had a low Framingham risk score and no signs of coronary atherosclerosis. Adjusted for physical
height, cardiac performance was not impaired compared with healthy subjects.
Conclusion: The present case report does not lend support to routine cardiovascular screening in patients with
extremely low circulating IGF-I levels due to a homozygous IGFALSmutation, when cardiovascular risk is low.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license. 1. Introduction
The protein Acid-Labile Subunit (ALS) plays an important role in
prolonging the half-life of insulin-like growth factor-I (IGF-I) and its
principal binding protein IGF binding protein-3 (IGFBP-3) in the
circulation. At present, 21 patients with homozygous or compound
heterozygous mutations in the IGFALS gene have been reported [1].
These IGFALS gene mutations all result in undetectable or extremely
low circulating ALS levels and, consequently, extremely low circulating
levels of IGF-I. During childhood, these patients are characterized by
growth retardation and a mild insulin resistance. In adulthood,ter/University of Amsterdam,
gdreef 9, 1105 AZ Amsterdam,
669343.
).
vier OA license. however, less is known about the clinical presentation of ALS
deﬁciency.
Low IGF-I levels in healthy middle-aged populations have been
associated with increased risk of ischemic heart disease [2–4] and
increased risk of developing congestive heart failure [5]. Additionally,
once heart failure is clinically present, it has been shown that low
IGF-I levels are associated with a worse prognosis [6,7]. Furthermore,
patients with adult onset growth hormone deﬁciency (AGHD) and
subsequent low IGF-I levels generally have a reduced peak exercise
cardiac performance and an increased atherosclerotic burden that is
reﬂected by an increased intima media thickness of the carotid
arteries [8]. These ﬁndings suggest that low IGF-I status in adulthood
may have implications for the development or progression of
cardiovascular disease (CVD).
In this context, an extremely low IGF-I status from childhood
onwards (as seen in ALS deﬁcient patients) might be expected to
Table 1
Glucose and lipid proﬁle.
Reference values
Total cholesterol (mmol/l) 7.2 0.0–6.5
LDL cholesterol (mmol/l) n.a. 3.50–4.50
HDL cholesterol (mmol/l) 1.2 N0.90
Triglycerides (mmol/l) 4.8 0.80–2.00
Glucose (mmol/l) 5.6 4.0–5.6
HbA1C (%) 5.6 4.0–6.0
HbA1C (mmol/mol) 38 20–42
Insulin (mU/l) 11 8–20
N.a.: not applicable.
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cardiac function, warranting routine cardiovascular screening in
adults that carry an IGFALS mutation. Therefore, we evaluated the
cardiovascular risk proﬁle, including cardiac performance and
atherosclerotic disease burden, in a 27 year old patient carrying a
homozygous IGFALS genemutation [9]. Furthermore, we reviewed the
currently existing literature concerning low IGF-I in adulthood and its
possible involvement in the development of CVD.
2. Methods
2.1. Evaluation of cardiovascular risk proﬁle
In order to assess the global cardiovascular risk proﬁle, a
cardiovascular medical history was taken and a physical examination
was performed. Additionally, total body fat percentage was measured
with a DEXA scan. An electrocardiogram (EKG) at rest was made to
detect the possible presence of axis deviation, rhythm disturbances or
ischemia-related changes in conformation. Fasting venous blood was
drawn to determine the lipid and glucose proﬁle. The patient gave
written informed consent for publication of current data.
2.2. Evaluation of atherosclerosis in coronary arteries
In order to evaluate the presence of subclinical premature
atherosclerosis in the coronary arteries, we performed 64-slice CT
scanning of the heart (Brilliance 64, Philips Medical Systems,
Cleveland, OH). Scan protocol and image reconstruction have been
described in detail previously [10,11].
2.3. Cardiac performance
Cardiac performance was assessed by conventional echocardio-
graphic evaluation, three dimensional (3D)-echocardiography, and
tissue deformation imaging (both Doppler and speckle-tracking
derived). Echocardiographic examination was performed with the
patient at rest, lying in a left lateral decubitus position. Ultrasound
data were acquired using a Vivid 7 scanner (GE Vingmed ultrasound,
General Electric, Milwaukee, Wis) with a broadband M3S ultrasound
probeandamatrix-arrayprobe for the3D image acquisition. A complete
echocardiographic analysis was performed in two-dimensional
(B-mode) and tissue Doppler imaging (TDI) modes. For 3D-echocar-
diographic examination we used a matrix transducer for transthoracic
apical acquisitions during a 5–7 s breath-hold. Carewas taken to include
the entire LV volume within the pyramid-shaped 3D scan-volume.
Commercially available software (4D LV-Analysis, TomTec Imaging
Systems, Munich, Germany) was used for quantiﬁcation of global LV
function. Diastolic function was assessed by pulsed wave Doppler
(inﬂow velocities and mitral annular velocities). Both standard
parasternal views (long and short axis) and apical views (4-, 2- and
3-chamber) were obtained. In order to detect differences in ventricular
wall motion, we performed tissue deformation imaging. For more
detailed information we refer to prior published work [12].
3. Results
3.1. General patient characteristics
For an extensive description of the patient with regard to the IGFALS
mutation and its associated phenotype, we refer to our prior published
report [9]. In short, the patient was born at term (weight and length
unreported) as the eldest of four children of consanguineous Kurdish
parents. He had a signiﬁcant delay in puberty onset and his growth
curve, from the age of 14 years onwards, ran parallel to (but far below)
the−2 SDS growth line of the Turkish reference diagram. He reached a
ﬁnal height of 149.7 cm (−4.2 SDS). At the age of 16 years, he wasreferred to a university hospital for analysis of his growth impairment.
During cardiologic investigation a grade I mitral valve and a mild
tricuspid valve insufﬁciency were detected. At the age of 20 years,
extensive biochemical evaluations revealed an elevated growth
hormone (GH) peak of 63 mU/l after exercise (equivalent to 21 μg/l,
conversion rate 1 μg/l=3.0 IU, standard WHO IS 110 98/574), and
signiﬁcantly decreased levels of both IGF-I (16–38 ng/ml,−6.9 to−5.0
SDS) and IGFBP-3 (0.2 mg/l,−12.0 SDS). There was a poor response to
GHwith two different doses (0.8 and 1.6 mg/m2) in an IGF-I generation
test: on the low GH dose IGF-I did not rise (38 and 35 ng/ml) but on the
higher GH dose IGF-I increased from 16 to 60 ng/ml. IGFBP-3 did not
change in this test. ALS was not detectable in plasma.
3.2. Evaluation of cardiovascular risk proﬁle
At the time of cardiovascular risk assessment our patient was
27 years of age. He had no positive family history with regard to
premature cardiovascular disease, atherothrombosis or type 2 diabe-
tes. He did not use anymedication or over the countermedication, nor
did he smoke. His height was 149.7 cm and body weight was 50 kg,
resulting in a BMI of 22.3 kg/m2. Body surface area (BSA), calculated
with the DuBois and DuBois formula [13], was 1.43 m2. A continuous
automatic blood pressure registration for 30 min revealed an average
blood pressure of 120/75 mm Hg with a regular pulse rate (measured
in rest and in supine position) of 60 bpm. Total body fat percentage
was estimated at 25%. The EKG did not show any abnormalities such as
rhythm disturbances or ischemia related changes in conformation.
Results of fasting venous blood sampling analysis are presented in
Table 1. Our patient showed borderline mild insulin resistance and
total cholesterol and triglyceride levels were elevated. No micro-
albuminuria was present. A Framingham risk score revealed an
individual risk of 1% for a cardiovascular event in 10 years.
3.3. Evaluation of atherosclerosis in coronary arteries
Multi-slice CT-scanning of the heart did not reveal any atherosclerotic
lesion in all evaluated coronary segments. No atherosclerotic plaques,
coronary calciﬁcations or other abnormalities were found in the right and
left coronary artery system (Fig. 1). No increased deposition of calcium
was found on the aortic valves and no other cardiac abnormalities were
detected.
3.4. Cardiac performance
All conventional measures of anatomy and systolic and diastolic
function, measured by echocardiography, did not show any abnor-
malities (compared with reference values adjusted for sex, age and
BSA). There were no signs of valvular insufﬁciency. The 3D ﬁndings
are summarized in Table 2. Adjusted for patient's decreased BSA, all
variables were within reference ranges. The quantitative analysis for
abnormalities in regional deformation showed a normal wall strain






Fig. 1. Evaluation of coronary system and cardiac anatomy by multi-slice CT scanning. a and b: Volume rendered CT image of the coronary arteries. c, d, and e: Curved multiplaner
reconstructed images of the coronary arteries showing no coronary artery disease. RCA: right coronary artery; LAD: left anterior descending coronary artery; LCX: left circumﬂex
coronary artery.
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concordance with the speckle tracking ﬁndings.
4. Discussion
Adult subjects with low circulating IGF-I levels have been considered
to be at increased risk of developing premature atherosclerosis and/or
heart failure. Despite extremely low circulating IGF-I levels, due to an ALS
deﬁciency, our 27 year old patient had no increased cardiovascular risk
proﬁle, as reﬂected by the absence of any sign of (subclinical) coronary
atherosclerosis. The assumption that all patients with ALS deﬁciency and
subsequent low circulating IGF-I levels should be extensively screened for
cardiovascular disease after they reached adulthood should therefore be
reconsidered.
Literature about ALS deﬁciency has mainly focussed on the
consequences of low IGF-I levels on growth [14]. Very little is
known about the consequences on CVD. We should therefore be
aware that most of today's knowledge about low IGF-I levels and CVD
concerns data extrapolated from other clinical conditions that are
characterized by a low IGF-I status. In this respect it is important to
realize that IGF-I levels can be low for several reasons. First of all, IGF-I
levels can be low, but still within, or near to, the reference range, as a
consequence of the normal spread within the general population.Table 2
Cardiac performance assessed by 3D-echocardiographic analysis.
Absolute value BSA corrected Reference value [28]
End diastolic volume 84.6 ml 59.2 (ml/m2) 58.7±11.0 (ml/m2)
End systolic volume 35.4 ml 24.8 (ml/m2) 23.6±5.8 (ml/m2)
Stroke volume 49.2 ml – 48.3±8.4 ml
Ejection fraction 58.2% – 60.1±3.2%Secondly, congenital GH deﬁciency (GHD) or GH Insensitivity Syndrome
(Laron syndrome) lead to extremely low circulating IGF-I levels. In the
third place, extremely low IGF-I levels can also be caused by adult onset
GH deﬁciency (AGHD) as a result of (pan)hypopituitarism after
hypophysectomy or irradiation of the pituitary gland, because of a
pituitary adenoma. In patients with GH deﬁciency or insensitivity, IGF-I
is not only low in the circulation, but also in all GH-responsive tissues.
Fourthly, circulating IGF-I can be low due to ALS deﬁciency, where the
tissue IGF-I is assumed to be normal. Hence, patients with a low IGF-I
status should be considered a heterogenous population and cannot be all
lumped in the same category.
The association between low IGF-I levels and CVD has mainly been
studied in healthy populations and in patientswith AGHD. Epidemiologic
studies in healthy populations have demonstrated an association
between low IGF-I levels and increased risk of ischemic heart disease
or heart failure [2–5]. It should be acknowledged, however, that subjects
included in these studies generally were middle aged or older, which
makes it complicated to extrapolate the results to young adultswho have
extremely low IGF-I levels from childhood onwards. Furthermore, there
are alsomany recent prospective cohort studieswhich did not observe an
association between IGF-I levels and (ischemic) heart disease [15–20],
and one prospective study even reported a decreased risk of heart failure
when IGF-I levels were low [18]. Taken together, the role of IGF-I status
on CVD in healthy middle aged subjects is currently unclear.
Adults with untreated GH deﬁciency and subsequent low IGF-I
levels due to hypopituitarism, are known to have an increased risk of
premature atherosclerosis and decreased heart function [8]. The cause
of this increased CV risk is currently unknown. AGHD is often
accompanied by central adiposity, dyslipidemia and hypertension.
Consequently, patients with AGHD have a more than two-fold
increased prevalence of the metabolic syndrome in comparison with
controls [21] which could contribute to increased CV risk. Substitution
Fig. 2. Speckle tracking derived regional and global deformation. The regional deformation graphs are shown in the individual 16 LV-segments in the three different imaging planes
(LAX, A2C and A4C). The graphs show normal systolic deformation values as well as normal graph characteristics (i.e. no post-systolic shortening or dyskinesia), both indicative of
normal regional systolic function. LAX: apical long axis; A2C: apical 2-chamber; A4C: apical 4-chamber; AVC: aorta valve closure.
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reduce CV risk [8]. Whether this decrease in CV risk could also be
attained by substitution with IGF-I has not been studied. Furthermore,
it appears that inappropriate replacement of other hormones, like sex
hormones or corticoids, in hypopituitarism patients can contribute to
insulin resistance and CVD. Patients that receive glucocorticoid doses
of more than 20 mg/day have a worse metabolic proﬁle, with higher
BMI, total cholesterol, LDL-cholesterol, and triglycerides, compared
with patients receiving less than 20 mg/day [22]. Therefore, rigid
hormone substitution in patients with AGHD may inﬂuence CVD
development beyond low IGF-I status. This implicates that the raised
CV risk that accompanies AGHD can not only be attributed to low IGF-I
status. Hence, it is unwarranted to presume that patients with low
IGF-I levels due to AGHD are comparable to patients with low IGF-I
levels due to an IGFALS mutation with respect to cardiovascular risk
proﬁle and atherosclerosis.
Our patient has extremely low circulating IGF-I levels due to an
IGFALS mutation. Although we did not ﬁnd any effect of low
circulating IGF-I levels on atherosclerosis, we could not assure
whether his low IGF-I status might have harmful effects on heart
repair after a possible future cardiovascular event. Indeed, low serum
IGF-I levels have been associated with a poor prognosis after a
myocardial infarction [23,24]. Furthermore, with the currently
available laboratory tests, it is impossible to measure local auto-
crine/paracrine IGF-I secretion. Theoretically, patients with a genetic
ALS defect are expected to have a normal autocrine and paracrine
IGF-I production, which is probably the reason that their growth is far
less disturbed than in patients with a complete GH deﬁciency, GH
insensitivity syndrome (Laron syndrome) or IGF-I deﬁciency [14].
Additionally, ALS deﬁcient patients are expected to have normal or
even increased GH levels, which will stimulate autocrine and
paracrine IGF-I production. Local IGF-I status within the heart plays
an important role in the repair mechanisms after ischemia. IGF-I
overexpression within the heart of mice protects against myocyte
apoptosis and ventricular dilatation after infarction [25]. Moreover,
local IGF-I therapy in the heart after cardiac ischemia improves
myocardial function [26,27]. With an aging population of patients
with an IGFALS mutation, these observations could be of interest,especially for those patients with concomitant premature cardiovas-
cular disease in their family history. In these patients, both elevated
GH levels and local unaffected IGF-I production may prevent early
manifestations of symptoms of CVD. The normal cardiac performance
of our patient supports the assumption that local IGF-I production is
undisturbed in patients with ALS deﬁciency.
In summary, the consequences of low IGF-I levels due to IGFALS
mutations on cardiovascular disease development are currently
unknown. Epidemiologic studies which have assessed the association
between IGF-I levels andCVDare inconsistent andhave been performed
in populations that are not comparable to young adults with an IGFALS
mutation. Therefore, we extensively evaluated the cardiovascular
disease status in a 27 year old male patient with a homozygous IGFALS
mutation and subsequent low circulating IGF-I levels. Besides a mild
insulin resistance and lipid disturbances we did not ﬁnd any sign of
(subclinical) CVD. These results suggest that low circulating IGF-I status
due to an IGFALSmutation is not necessarily accompanied by increased
risk of CVD. Althoughwe think that ALS deﬁcient patients should not be
submitted to extensive cardiovascular screening when cardiovascular
risk is low,more research is needed, especially in older patientswithALS
deﬁciency. Future long-term prospective studies, including more and
older patients with IGFALSmutations, hopefully will elucidate whether
extreme low circulating IGF-I levels in these patients on a longer term
will affect CVD, or whether locally produced IGF-I will protect against
(progression) of CVD.Acknowledgments
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